Lixte Biotechnology Holdings, Inc. functions as a biopharmaceutical firm dedicated to the discovery and development of innovative therapeutic compounds. The company leverages advanced biomarker technology to create novel drug candidates aimed at combating severe and widespread human diseases. Its core research primarily concentrates on protein phosphatase inhibitors, which are being explored for standalone administration or in conjunction with cytotoxic agents, radiation therapy, and immune checkpoint blockers.